These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 15733743

  • 1. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
    Duran-Sandoval D, Cariou B, Fruchart JC, Staels B.
    Biochimie; 2005 Jan; 87(1):93-8. PubMed ID: 15733743
    [Abstract] [Full Text] [Related]

  • 2. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B.
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M.
    Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
    [Abstract] [Full Text] [Related]

  • 5. FXR: a promising target for the metabolic syndrome?
    Cariou B, Staels B.
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FXR: a metabolic regulator and cell protector.
    Wang YD, Chen WD, Moore DD, Huang W.
    Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L.
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [Abstract] [Full Text] [Related]

  • 11. Regulation of carbohydrate metabolism by the farnesoid X receptor.
    Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP.
    Endocrinology; 2005 Mar; 146(3):984-91. PubMed ID: 15564327
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S, Moschetta A.
    FEBS Lett; 2006 Oct 09; 580(23):5492-9. PubMed ID: 16904670
    [Abstract] [Full Text] [Related]

  • 17. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA.
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar 09; 290(3):G476-85. PubMed ID: 16269519
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T, Murakami K, Ozawa I, Minegishi Y, Kashimura R, Akita T, Saitou S, Atsumi T, Sato T, Ando K, Hara S, Kikugawa K, Hayakawa M.
    FEBS J; 2009 Mar 09; 276(5):1319-32. PubMed ID: 19187229
    [Abstract] [Full Text] [Related]

  • 19. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
    Campana G, Pasini P, Roda A, Spampinato S.
    Biochem Pharmacol; 2005 Jun 15; 69(12):1755-63. PubMed ID: 15935148
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.